Panic disorder with or without agoraphobia has been the subject of sustained treatment-outcome research. Studies have been conducted by both pharmacologically- and psychologically-oriented researchers each employing their own methodologies. Problems arise in attempting to reconcile the demands of these two treatment-outcome methodologies, whilst at the same time ensuring that research designs reflect the reality of wider clinical practice. In the following discussion a series of studies comparing pharmacological and psychological treatments for panic disorder and agoraphobia are reviewed. The review highlights areas where the competing demands of research design and clinical applicability lead to dilemmas for the researcher. Attempts to overcome such dilemmas are described and alternative solutions discussed.
AronsonTA (1987) A follow up study of two panic disorder-agoraphobia study populations. The role of recruitment biases. J Nerv Ment Dis175: 595-598
2.
Barlow D.H. (1988) Anxiety and its disorders: the nature and treatment of anxiety and panic. Guilford Press, New York
3.
Barlow D.H. (1989) Treatment outcome evaluation methodology with anxiety disorders: strengths and key issues. Adv Behav Res Ther11: 121-132
4.
Barlow D. (1994) Psychological interventions in an era of managed competition. Clin Psychol Sci Pract1:109-122
5.
Barr Taylor C, Kenigsberg M.L., Robinson J.M. (1982) A controlled comparison of relaxation and diazepam in panic disorder. J Clin Psychiat43: 423-425
6.
Black D.W., Wesner R., Bowers W., Gabel J. (1993) A comparison of fluvoxamine cognitive therapy and placebo in the treatment of panic disorder. Archs Gen Psychiat50: 44-50
7.
Charney D.S., Woods S.W., Goodman W.K., Rifkin B., Kinch M., Aiken B., Quadrino L.M., Heninger G.R. (1986) Drug treatment of panic disorder: the comparative efficacy of imipramine alprazoloam and trazodone. J Clin Psychiat47: 580-586
8.
Clark D.B., Barr-Taylor C., Roth W.T., Hayward C., Ehlers A., Margraf J., Agras W.S. (1990) Surreptitious drug use by patients in a panic disorder study. Am J Psychiat147: 507-509
9.
Clark DM, Salkovskis PM, Hackman A., Middleton H., Anastasiades P., Gelder M. (1994) A comparison of cognitive therapy applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiat164: 759-769
10.
Clum G.A. (1989) Psychological interventions vs drugs in the treatment of panic. Behav Ther20: 429-457
11.
Cottraux J., Note I., Cungi C., Legeron P., Heim F., Chneiweiss L., Bernard G.Bouvard M. (1995) A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. BrJ Psychiat167: 635-641
12.
De Beurs E., Lange A., Van Dyke R. (1992) Self monitoring of panic attacks and retrospective estimates of panic: discordant findings. Behav Res Ther30: 411-413
13.
De Beurs E., Van Balkom A.J., Lange A., Koele P., Van Dyke R. (1995) Treatment of panic disorder with agoraphobia: comparison of fluvoxamine placebo and psychological panic management combined with exposure and of exposure alone. Am J Psychiat152: 683-691
14.
DiNardo PA, Barlow D.H. (1988) Anxiety disorders interview schedule revised (ADIS-R) . Graywinds, New York
15.
Diagnostic and statistical manual of mental disorders (3rd edn, 3rd edn. rev., 4th edn). American Psychiatric Association, Washington DC
16.
FahyTJ, O'Rourke D., BrophyJ., Schazmann W., Sciascia S. (1992) The Galway study of panic disorder 1: clomipramine and lofepramine in DSM III-R panic disorder a placebo controlled trial. J Affect Dis25: 63-76
17.
Fossey M.D., Lydiard B. (1990) Placebo response in patients with anxiety disorders . In Noyes R, Roth M, Burrows G (eds), Handbook of anxiety disorders, Vol. 4, The treatment of anxiety. Elsevier, Amsterdam
18.
Gould R.A., Otto M.W., Pollack M.H. (1995) A meta-analysis of treatment outcome for panic disorder. Clin Psychol Rev15: 819-844
19.
Hegel M.T., Ravaris C.L., Ahles T.A. (1994) Combined cognitive-behavioural and time limited alprazolam treatment of panic disorder. Behav Ther25:183-195
20.
Hollon S.D., De Rubies R.J. (1981) Placebo-psychotherapy combinations: inappropriate representations of psychotherapy in drug-psychotherapy comparative trials . Psychol Bull90: 467-477
21.
Jacobson N.S., Truax P. (1991) Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. J Cons Clin Psychol59: 12-19
22.
Jacobson N.S., Hollon S.D. (1996) Cognitive-behaviour therapy versus pharmacotherapy: now that the jury's returned its verdict it's time to present the rest of the evidence. J Cons Clin Psychol64: 74-80
23.
Katerndahl DA (1990) Infrequent and limited symptom panic attacks. J Nerv Ment Dis178: 313-317
24.
Kendall P.C., Lipman A.J. (1991) Psychological and pharmacological therapy: methods and modes for comparative outcome research. J Cons Clin Psychol59: 78-87
25.
King M. ( 1997) Brief psychotherapy in general practice: how do we measure outcome?Br J Gen Pract47:136-137
26.
Kingdon D., Tyrer P., Seiverwright N., Ferguson B., Murphy S. (1996) The Nottingham study of neurotic disorder: influence of cognitive therapists on outcome. Br J Psychiat169: 93-97
27.
Klein D.F. (1996) Preventing hung juries about therapy studies. J Cons Clin Psychol64: 81-87
28.
Klosko J.S., Barlow D.H., Tassinari R., Cerny JA (1990) A comparison of alprazolam and behaviour therapy in treatment of panic disorder. J Cons Clin Psychol58: 77-84
29.
Marks I.M., Gray S., Cohen D., Hill R., Mawson D., Ramm E., Stern R.S. (1983) Imipramine and brief therapist aided exposure in agoraphobics having self exposure homework. Archs Gen Psychiat40: 153-162
30.
Marks I.M., Swinson R.P., Basoglu M., Kuch K., Noshirvani H., O'Sullivan G., Lelliot P.T., Kirby M., McNamee G., Sengun S., Wikwire K. (1993) Alprazolam and exposure alone and combined in panic disorder with agoraphobia. Br J Psychiat162: 776-787
31.
Mathews AM, Gelder MG, Johnston DW (1981) Agoraphobia nature and treatment. Guilford Press, New York
32.
Mavissakalian M. (1990) Sequential combination of imipramine and self directed exposure in the treatment of panic disorder with agoraphobia. J Clin Psychiat51:184-188
33.
Mavissakalian M., Michelson L., Dealy R. (1983) Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice. Br J Psychiat143: 348-355
34.
McNally R.J. (1996) Methodological controversies in the treatment of panic disorder. J Cons Clin Psychol64: 88-91
35.
Mellergard M., Rosenberg N.K. (1990) Patterns of response during placebo treatment of panic disorder. Acta Psychiat Scand81: 340-344
36.
Michelson L., Mavissakalian M. (1985) Psychophysiological outcome of behavioural and pharmacological treatments of agoraphobia. J Cons Clin Psychol53: 229-236
37.
Oehrberg S., Christiansen P.E., Behnke K., Borup A.L., Severin B., Soegard J., Calberg H., Judge R., Onrstrom J.K., Manniche P.M. (1995) Paroxetine in the treatment of panic disorder a randomised double blind placebo controlled study. Br J Psychiat167: 374-379
38.
Ost LG, Westling BE, Hellstrom K. (1993) Applied relaxation exposure in vivo and cognitive methods in the treatment of panic disorder with agoraphobia. Behav Res Ther31: 383-394
39.
Otto MW, Gould RA, McLean Rys (1996) The effectiveness of cognitive-behaviour therapy for panic disorder without concurrent medication treatment: a reply to Power and Sharp. J Psychopharmac10: 254-256
40.
Parloff M.B. (1986) Placebo controls in psychotherapy research: a sine qua non or a placebo for research problems?J Cons Clin Psychol54: 79-87
41.
Power KG, Simpson RJ, Swanson V., Wallace L., Feistner Atg, Sharp D.M. (1990) A controlled comparison of cognitive behavioural therapy diazepam and placebo alone and in combination in the treatment of generalised anxiety disorder. J Anx Dis4: 267-292
42.
Power KG, Sharp DM (1995) Keep taking the tablets? Inadequate controls for concurrent psychotropic medication in studies of psychological treatments for panic disorder. J Psychopharmac9: 71-72
43.
Rapee RM, Craske MG, Barlow D.H. (1990) Subject described features of panic attacks using self monitoring. J Anx Dis4: 171-181
44.
Rogers C. (1957) The necessary and sufficient conditions of therapeutic change. J Cons Psychol21: 95-103
45.
Schwartz D., Lellouch J. (1967) Explanatory and pragmatic attitudes in therapeutic trials. J Chron Dis20: 637-648
46.
Sharp D.M., Power KG, Simpson R.J., Swanson V., Moodie E., Anstee JA, Ashford JJ (1996) Fluvoxamine placebo and cognitive behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia . J Anx Dis10: 219-242
47.
Sharp D.M., Power KG, Simpson R.J., Swanson V., Anstee JA (1997) Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder in primary care. Br J Gen Pract47:150-155
48.
Shear M.K., Maser J.D. (1994) Standardised assessment for panic disorder research: a conference report. Archs Gen Psychiat51: 346-354
49.
Spitzer R.L., Williams J B W, Gibbon M., First M.B. (1988) Structured clinical interview for DSM III-R patient version. Research DepartmentNew York State Psychiatric Institute, New York
50.
Telch MJ, Agras WS, Barr Taylor C., Roth W., Gallen C.G. (1985) Combined pharmacological and behavioural treatment for agoraphobia. Behav Res Ther23: 325-335
51.
Tobena A., Sanchez R., Pose R., Masana J., Del Campo A.M. (1990) Brief treatment with alprazolam and behavioural guidance in panic disorder. Anx Res3:163-174
52.
Wittchen HU, Essau CA (1993) Epidemiology of panic disorder: progress and unresolved issues. J Psychiat Res27: 47-68
53.
Wolfe BE, Maser J.D. (1994) Treatment of panic disorder: a consensus development conference. American Psychiatric Press, Washington DC
54.
Zitrin C.M., Klein D.F., Woerner M.G. (1980) Treatment of agoraphobia with group exposure in vivo and imipramine. Archs Gen Psychiat37: 63-72
55.
Zitrin C.M., Klein D.F., Woerner M.G., Ross D.C. (1983) Treatment of phobias. 1. Comparison of imipramine hydrochloride and placebo. Archs Gen Psychiat40:125-138
